Literature DB >> 2835573

Interstitial pneumonitis after allogeneic bone marrow transplantation. Nine-year experience at a single institution.

J R Wingard1, E D Mellits, M B Sostrin, D Y Chen, W H Burns, G W Santos, H M Vriesendorp, W E Beschorner, R Saral.   

Abstract

Of 386 patients with allogeneic bone marrow transplants (BMT) treated during a 9-year interval, 166 developed interstitial pneumonitis (IP). Idiopathic and cytomegalovirus (CMV) IP constituted 90% of the 113 cases in which tissue was examined. Risk factors for IP overall were acute graft-versus-host disease (AGVHD), remote transplant date, the diagnosis of leukemia, and GVHD prophylaxis with agents other than cyclosporine. Risk factors for CMV IP were pre-transplant CMV seropositivity, CMV excretion, age greater than 10 years, AGVHD, GVHD prophylaxis with agents other than cyclosporine, and a remote transplant date. Patients transplanted for aplastic anemia were at lower risk for idiopathic IP than those transplanted for leukemia. The incidence of IP in patients given busulfan plus cyclophosphamide was equivalent to that in patients receiving cyclophosphamide plus total body irradiation. The incidence of idiopathic IP remained constant over this 9-year period while CMV IP declined significantly.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2835573     DOI: 10.1097/00005792-198805000-00004

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  23 in total

1.  Radiation-induced changes in lung tissue and development of fibrosis determined by quantitative morphometric methods.

Authors:  R Kraus; F Steinberg; B Rehn; J Bruch; C Streffer
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 2.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

Review 3.  AIDS and the lung. 7. Treatment of lung disease in patients with the acquired immune deficiency syndrome.

Authors:  D M Mitchell; M A Johnson
Journal:  Thorax       Date:  1990-03       Impact factor: 9.139

Review 4.  Respiratory diseases.

Authors:  D G James; O M Sharma
Journal:  Postgrad Med J       Date:  1990-01       Impact factor: 2.401

5.  Risk factor analysis of idiopathic pneumonia syndrome after allogeneic hematopoietic SCT in children.

Authors:  H Sano; R Kobayashi; A Iguchi; D Suzuki; K Kishimoto; K Yasuda; K Kobayashi
Journal:  Bone Marrow Transplant       Date:  2013-08-19       Impact factor: 5.483

Review 6.  Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation.

Authors:  M F Siadak; K Kopecky; K M Sullivan
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

7.  The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.

Authors:  Gregory A Yanik; Vincent T Ho; John E Levine; Eric S White; Thomas Braun; Joseph H Antin; Joel Whitfield; Joseph Custer; Dawn Jones; James L M Ferrara; Kenneth R Cooke
Journal:  Blood       Date:  2008-07-29       Impact factor: 22.113

8.  Investigation and management of pulmonary infiltrates following bone marrow transplantation: an eight year review.

Authors:  J H Campbell; N Blessing; A K Burnett; R D Stevenson
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

9.  A role for TNF receptor type II in leukocyte infiltration into the lung during experimental idiopathic pneumonia syndrome.

Authors:  Gerhard C Hildebrandt; Krystyna M Olkiewicz; Leigh Corrion; Shawn G Clouthier; Elizabeth M Pierce; Chen Liu; Kenneth R Cooke
Journal:  Biol Blood Marrow Transplant       Date:  2008-04       Impact factor: 5.742

Review 10.  Viral infections in severely immunocompromised cancer patients.

Authors:  S M Devine; J R Wingard
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.